Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) will report fourth quarter and full year 2025 financial results and provide a business update via live webcast on Thursday, February 26, 2026 at 8:00 am EST.

Investors and media can access the live webcast and related materials on Phathom's Events & Presentations page; a recording will be available for 90 days after the call.

News Market Reaction

+6.16%

16 alerts

+6.16% News Effect

-5.1% Trough in 1 hr 45 min

+$58M Valuation Impact

$999M Market Cap

0.8x Rel. Volume

On the day this news was published, PHAT gained 6.16%, reflecting a notable positive market reaction. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $58M to the company's valuation, bringing the market cap to $999M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings call date: February 26, 2026 Earnings call time: 8:00 am EST Webcast replay duration: 90 days +2 more

5 metrics

Earnings call date February 26, 2026 Scheduled fourth quarter and full year 2025 results

Earnings call time 8:00 am EST Start time for live webcast and conference call

Webcast replay duration 90 days Recording availability following conclusion of the call

Media contact phone 1-877-742-8466 Media contact number provided in release

Investor contact phone 1-877-742-8466 Investor relations contact number in release

Market Reality Check

Price: $12.76 Vol: Volume 698,574 is at 75% ...

normal vol

$12.76 Last Close

Volume Volume 698,574 is at 75% of the 20-day average 929,707, suggesting muted trading into the announcement. normal

Technical Shares at $12.02 are trading above the 200-day MA of $11.26, after a strong move off the $2.21 52-week low but below the $18.31 52-week high.

Peers on Argus

Biotech peers show mixed moves, with names like EYPT and PRAX appearing in momen...

4 Up 1 Down

Biotech peers show mixed moves, with names like EYPT and PRAX appearing in momentum scans both up and down. With PHAT flat on the day and no clear directional cluster among peers, the earnings-date headline appears stock-specific rather than part of a sector-wide swing.

Historical Context

5 past events · Latest: Feb 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Conference presentation	Neutral	-6.2%	Guggenheim biotech summit fireside chat and meetings announcement.
Jan 07	Offering priced	Negative	+10.4%	Pricing of $130M common stock and pre-funded warrant offering.
Jan 07	Offering proposed	Negative	+10.4%	Proposed equity and pre-funded warrant offering from effective shelf.
Jan 07	Prelim earnings 2025	Positive	+10.4%	Preliminary 2025 revenues, expenses, cash, and profitability outlook.
Nov 04	Clinical trial start	Positive	-1.8%	First patient dosed in Phase 2 VOQUEZNA EoE study.

Pattern Detected

Recent news has often produced sizable moves, with positive fundamental updates (prelim 2025 results) aligning with gains, while offerings and clinical milestones have sometimes seen mixed or negative follow-through.

Recent Company History

Over the past few months, Phathom has combined financing, clinical progress, and financial updates. On Jan 7, 2026, it reported preliminary Q4 and full-year 2025 results alongside a public offering that raised about $130M, with the stock rising around 10.45%. A Phase 2 EoE trial first-patient dosing on Nov 4, 2025 saw a modest decline, while a February 2026 conference appearance coincided with a pullback. Against this backdrop, today’s scheduling of the formal 2025 earnings call fits into an ongoing narrative of commercial ramp and capital access.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-01-07

An automatic Form S-3ASR shelf filed on 2026-01-07 is effective, allowing Phathom to issue various securities via future prospectus supplements. Recent 424B5 filings on Jan 7–8, 2026 indicate this capacity has already been used for an underwritten equity and pre-funded warrant offering, so investors should be mindful of potential future capital raises under the same shelf.

Market Pulse Summary

The stock moved +6.2% in the session following this news. A strong positive reaction aligns with inv...

Analysis

The stock moved +6.2% in the session following this news. A strong positive reaction aligns with investors refocusing on fundamentals ahead of confirmed earnings events. The company already shared preliminary 2025 figures on Jan 7, 2026, and today’s notice mainly locks in the formal release and business update on Feb 26, 2026. Prior moves around offerings and clinical milestones show that sentiment can swing sharply, and the existing S-3ASR shelf plus recent equity usage may temper how long any earnings-date bump persists.

Key Terms

potassium-competitive acid blocker, pcab, non-erosive gerd, erosive gerd, +1 more

5 terms

potassium-competitive acid blocker medical

"vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S."

A potassium-competitive acid blocker is a type of medication that reduces stomach acid by blocking the cellular “pump” that produces acid, using a chemical that competes with potassium to stop the pump from working. For investors, it matters because this drug class can offer faster, longer-lasting acid control than older therapies, affecting market demand, pricing power, regulatory scrutiny, and commercial potential in conditions like ulcers and reflux.

pcab medical

"vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S."

PCAB is the Philippine Contractors Accreditation Board, the government body that issues licenses and size classifications to construction contractors—think of it like a combined business license and capacity rating for builders. Investors pay attention because a contractor’s PCAB license and grade determine which public and private projects it can legally bid on and the maximum project size it may undertake; changes in status can directly affect a firm’s revenue opportunities and regulatory risk profile.

non-erosive gerd medical

"VOQUEZNA ... for the relief of heartburn associated with Non-Erosive GERD in adults"

Non-erosive GERD is a form of acid reflux where people experience typical symptoms such as heartburn and regurgitation but endoscopic exams show no visible injury to the lining of the esophagus. Think of it like a smoke alarm going off without any visible fire — the problem causes discomfort but isn’t showing obvious tissue damage. It matters to investors because this subtype often responds differently to treatments, affects trial design and patient selection, and represents a large patient group that shapes market size, pricing and reimbursement for therapies.

erosive gerd medical

"the healing and maintenance of healing of Erosive GERD in adults"

Erosive GERD is a form of acid reflux where stomach acid not only flows back into the food pipe but actually damages its lining, creating visible sores or erosion. Investors should care because this more severe, measurable form of reflux generally requires stronger or long‑term treatments, drives demand for prescription drugs, medical procedures and diagnostics, and is a common clinical endpoint in regulator and payer decisions that affect company revenues.

h. pylori medical

"VOQUEZNA TRIPLE PAK ... for the treatment of H. pylori infection in adults."

A common stomach bacterium that can live in the lining of the stomach and upper intestine, often causing chronic inflammation, sores (ulcers), and increasing the risk of stomach cancer. For investors, H. pylori matters because testing, treatments and vaccines create ongoing markets for diagnostics, pharmaceuticals and public-health programs, and shifts in infection rates, drug resistance or new therapies can change revenue and regulatory risk for companies in those areas.

AI-generated analysis. Not financial advice.

Management to host conference call on Thursday, February 26, 2026, at 8:00 am EST

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

When will Phathom Pharmaceuticals (PHAT) report Q4 and full year 2025 results?

Phathom will report results on Thursday, February 26, 2026 at 8:00 am EST. According to the company, the event includes a webcast covering fourth quarter and full year 2025 financial results and a business update.

How can investors access the Phathom (PHAT) February 26, 2026 webcast?

Investors can access the live webcast on Phathom's Events & Presentations page. According to the company, the presentation materials and a recording (available for 90 days) will be posted on the investor website.

Will Phathom (PHAT) make the February 26, 2026 earnings recording available later?

Yes. According to the company, a recording of the webcast will be available for 90 days after the conclusion of the call. The recording and supplemental materials will be on the Events & Presentations page.

What topics will Phathom (PHAT) cover during the February 26, 2026 presentation?

The company will present fourth quarter and full year 2025 financial results and provide a business update. According to the company, the webcast will include management commentary and supplemental investor information.

Who are the media and investor contacts for Phathom (PHAT) regarding the February 26, 2026 call?

Media contact is Nick Benedetto and investor contact is Eric Sciorilli, reachable at the phone number and emails listed by the company. According to Phathom, both contacts are available for follow-up inquiries.

What products and focus will Phathom (PHAT) likely reference in its February 26, 2026 update?

Phathom is focused on gastrointestinal treatments and markets vonoprazan-based VOQUEZNA products in the U.S. According to the company, discussion may reference vonoprazan commercial activities and business developments related to those products.